The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population

References

• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Lond. Engl. 2017;390:1211–1259.
   PubMed Web of Science ®Google Scholar
• McEvoy JP. The costs of schizophrenia. J Clin Psychiatry. 2007;68(Suppl 14):4–7.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771.
   PubMed Web of Science ®Google Scholar
• Khaykin E, Eaton WW, Ford DE, et al. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv. 2010;61(8):830–834.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2020. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Third ed. Washington (DC): American Psychiatric Association Publishing.
   Google Scholar
• Hasan A, Falkai P, Wobrock T, WFSBP Task Force on Treatment Guidelines for Schizophrenia, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–170.
   PubMed Web of Science ®Google Scholar
• Werner F-M, Coveñas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf. 2014;13(8):1031–1042.
   PubMed Web of Science ®Google Scholar
• Divac N, Prostran M, Jakovcevski I, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Bertsch J, et al. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531–540.
   PubMed Web of Science ®Google Scholar
• Tenback DE, van Harten PN, Slooff CJ, et al. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol. 2010;24(7):1031–1035.
   PubMed Web of Science ®Google Scholar
• Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14(3):152–164.
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann of Clinical Psychiatry. 2002;14(2):123–129.
   PubMedGoogle Scholar
• Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: Implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–viii.
   PubMed Web of Science ®Google Scholar
• McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual. Qual Life Res. 2019;28(12):3303–3312.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Nyhuis AW, Stauffer V, et al. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin. 2010a;26(10):2403–2410.
   PubMed Web of Science ®Google Scholar
• Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010b;10:2.
   PubMed Web of Science ®Google Scholar
• Abouzaid S, Tian H, Zhou H, et al. Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia. Community Ment Health J. 2014;50(1):51–58.
   PubMed Web of Science ®Google Scholar
• IBM. MarketScan research databases [WWW Document]; 2020 [cited 2021 Jan 26]. Available from: https://www.ibm.com/products/marketscan-research-databases/databases.
   Google Scholar
• United States Congress, 1996. Health Insurance Portability and Accountability Act of 1996. Pub L No 104–191. Date Enacted: August 21, 1996. Available from: https://www.govinfo.gov/content/pkg/PLAW-104publ191/html/PLAW-104publ191.htm
   Google Scholar
• Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. JMCP. 2008;14(4):352–362.
   PubMed Web of Science ®Google Scholar
• Johnson DA, Lieberman D, Inadomi JM, et al. Increased post-procedural non-gastrointestinal adverse events after outpatient colonoscopy in high-risk patients. Clin Gastroenterol Hepatol. 2017;15(6):883–891.e9.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Consumer price index [WWW document]; 2021 [cited 2021 Mar 30]. Available from: https://www.bls.gov/cpi/.
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122(1-3):1–23.
   PubMed Web of Science ®Google Scholar